This is a national, multicentric, prospective, observational trial. The decision to prescribe FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab must have been freely taken by the clinician prior to the study entry for each patient included. Each physician will see his/her patients within the context of routine visits, without any special visit being organised for the purposes of the study. Therefore, the doctor-patient relationship and patient follow-up are not modified. Physicians are totally free to decide on their patients' therapeutic management. EORTC QLQ-C30 and DLQI questionnaires will be completed by the patients at baseline (Day 1 of Cycle 1), at the first day of every other cycle (every 2 weeks) thereafter, and at ""End of Study Visit" (within 28 days from the end of treatment with anti-EGFR or withdrawal from study for any reason). Before every cycle, adverse events will be recorded and graded according to NCI CTCAE v4.0. Treatment's modifications in terms of cycles' delay, dose reductions or drugs' interruptions will be recorded. Concomitant approaches to prevent or treat dermatological toxicities during the treatment will be registered.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
EORTC QLQ C30 questionnaire score
Timeframe: 24 months
QoL questionnaire DLQI questionnaire score
Timeframe: 24 months
%of enrolled subjects, experiencing a specific adverse event according to NCI CTC-AE version 4.0
Timeframe: 24 months
Recording of number of concomitant medications, to prevent or treat dermatological adverse events
Timeframe: 24 months
Time to onset of the dermtological toxicity
Timeframe: 24 months
Dose reduction
Timeframe: 24 months
"number of administered cycles"
Timeframe: 24 months
average relative dose intensity of every drug"
Timeframe: 24 months